BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced a clinical trial collaboration and supply agreement (the “Agreement”) with Incyte (NASDAQ:INCY), a global biopharmaceutical company focused on discovering and developing novel therapeutics in oncology and other serious diseases.
The post BriaCell Announces Clinical Trial Collaboration Agreement with Incyte appeared first on Investing News Network.
Original Article: BriaCell Announces Clinical Trial Collaboration Agreement with Incyte